Selective agonist of dopamine D2 receptor (DRD2) and application thereof in treatment of diseases
A technology of precursors and isomers, applied in the field of discovery of dopamine D2 receptor selective agonists, can solve problems such as hallucinations and movement disorders
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0154] The present invention also provides a method for preparing a pharmaceutical composition or preparation for treating low dopamine-related diseases, the method comprising: mixing a therapeutically effective amount of a compound of formula I with a pharmaceutically acceptable carrier to form a pharmaceutical composition or preparation.
[0155] Typically, administering a therapeutically effective amount of a compound of formula I, or a pharmaceutical composition or preparation comprising a compound of formula I, to a subject can treat or alleviate low dopamine-related diseases (eg, Parkinson's).
[0156] DRD2 selective agonists and uses thereof
[0157] The invention provides a DRD2 selective agonist.
[0158] In a preferred example of the present invention, based on the complex structure of DRD2 and the antagonist haloperidol, the inventors continuously optimized the design and synthesized a DRD2 selective agonist by chemical method.
[0159] In another preferred exampl...
Embodiment 1
[0181] Embodiment 1 A kind of dopamine D 2 Discovery and Characterization of Receptor Selective Agonists
[0182] Inventor based on D 2 Based on the structural information of the receptor, a DRD2 selective agonist ( figure 1 ). The inventors selected two signaling pathways downstream of the receptor, the G protein signaling pathway and the β-arrestin signaling pathway, as indicators of the degree of receptor agonism, and verified their selectivity at the cellular level.
[0183] result( figure 2 ) shows that the performance of this agonist in the two signaling pathways is similar, whether it is for the activation of the G protein signaling pathway downstream of the dopamine receptor or for the activation of the β-arrestin signaling pathway under the dopamine receptor, the agonist has the same effect. Cannot activate DRD4, partially activate DRD3, fully activate DRD2, and the EC when this agonist plays a role in DRD3 50The value is about 15 times that of DRD2, which shows...
Embodiment 2
[0184] Embodiment 2 dopamine D 2 Application of receptor selective agonists in the treatment of animal models of Parkinson's disease
[0185] The inventors tested the neuroprotective effect of DRD2 agonist in the MPTP-induced Parkinson's disease mouse model, meanwhile, the Parkinson's disease drug pramipexole served as a positive control. result( image 3 ) showed that this agonist can relieve the MPTP-induced decrease in the expression of dopamine synthase tyrosine hydroxylase (TH) in the substantia nigra of the brain, revealing that it has a protective effect on dopaminergic neurons in the substantia nigra, And its effect is better than pramipexole (DRD2 / DRD3 / DRD4 agonist), which is currently clinically used to treat Parkinson's disease, which further suggests that this DRD2 agonist has the potential to treat Parkinson's disease more effectively.
PUM
![No PUM](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/noPUMSmall.5c5f49c7.png)
Abstract
Description
Claims
Application Information
![application no application](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/application.06fe782c.png)
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap